Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.

The devastating retrovirus HTLV-1 has eluded scientists for decades. Overcoming chronic funding and other challenges, ...